Stock Ratings / Health Care / SNGX / earnings

LEXX (47) MTVA (47) TCRT (31) KPRX (32) ⌘ Pro Terminal →

Soligenix Inc. (SNGX) Next Earnings Date & Expected ±12.5% Move

$0.37 -1.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Soligenix Inc. (SNGX) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $8.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNGX)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.05 Expected Swing

MODEL EARNINGS SETUP GAUGE

SNGX Quantitative Pre-Earnings Setup: 44/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (44/100)Model Risk Weight (56/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$11.1M	-$10.3M	52%
FY 2024	2024-12-31	$119.4K	-$8.3M	-$8.4M	0%
FY 2023	2023-12-31	$839.4K	-$6.1M	-$8.6M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNGX)

✓Walkthrough of SNGX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SNGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.71%⚡ TESTING RESISTANCE

2026-10-30O $0.38H $0.38L $0.34C $0.37VOL 69.4K

RES: $0.38SUP: $0.30SMA50: $0.37SMA200: $0.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNGX Butterfly Map → + Track SNGX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNGX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SNGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNGX)

Health Care Rank #529 of 1016 ⚔️ LEXX vs SNGX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNGX vs. LEXX, MTVA, TCRT, KPRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Soligenix Inc. (SNGX) ranks #529 by composite RQD confidence (44/100, grade D) and #910 by equity capitalization ($8.0M). Within this direct 5-issuer industry benchmark cohort, SNGX leads on earnings valuation at N/A trailing P/E, while SNGX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LEXX currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SNGX at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SNGX ACTIVE Soligenix Inc.	D	44/100	—	—	-35.0%	-1.55%	$8.0M	Benchmark Subject
LEXX Lexaria Bioscience Corp.	D	47/100	—	96.0%	-35.0%	+14.24%	$7.9M	/lexx-vs-sngx →
MTVA MetaVia Inc.	D	47/100	—	—	-35.0%	+4.39%	$7.8M	/mtva-vs-sngx →
TCRT Alaunos Therapeutics Inc.	E	31/100	—	—	-35.0%	-11.27%	$7.8M	/tcrt-vs-sngx →
KPRX Kiora Pharmaceuticals Inc.	E	32/100	—	—	-35.0%	-25.42%	$7.8M	/kprx-vs-sngx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000812796

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Soligenix Inc. (SNGX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $119.4K , and -100.0% cumulative change since FY2023) , GAAP net income of -$11.1M, operating cash flow of -$10.3M, and free cash flow of -$10.3M (-22.2% YoY). On the balance sheet, SNGX closed FY2025 with $9.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.1M	-$10.3M	-$10.3M	$9.2M	—
FY2024 (FY)	2024-12-31	$119.4K	-$8.3M	-$8.4M	-$8.4M	$9.0M	—
FY2023 (FY)	2023-12-31	$839.4K	-$6.1M	-$8.6M	-$8.6M	—	—

3. SNGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Soligenix Inc. (NASDAQ: SNGX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $0.37 (-1.55% 1D, market cap $8.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SNGX ranks #529 in composite RQD confidence.

How does SNGX compare to LEXX and MTVA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNGX carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LEXX (Lexaria Bioscience Corp.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $7.9M) and MTVA (MetaVia Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, SNGX leads on earnings multiple (N/A) while SNGX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SNGX?

Per SNGX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000812796), Soligenix Inc. generated $0 in revenue (-100.0% YoY), -$11.1M in net income, and -$10.3M in free cash flow against $9.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SNGX trading relative to its 50-day, 200-day, and 52-week technical levels?

SNGX last traded at $0.37 (-1.55% on volume of 36,765 shares), positioning the stock 0.00% above its 50-day simple moving average ($0.37) and -45.59% below its 200-day simple moving average ($0.68). Across its 52-week range of $0.28 to $1.70, SNGX sits at the 6.3% percentile with a 14-day RSI of 49.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.42).